| |
Latest 10 SEC filings (by transaction date) for MRSN within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 3/24 | Apr 1/24 | Alleva Lawrence M | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 3,996 | |
Jan 17/24 | Jan 16/24 | Protopapas Anna | Direct Ownership | Common Stock | S - Open market or private sale | -29,399 | $2.71 |
Jan 17/24 | Jan 16/24 | Misra Tushar | Direct Ownership | Common Stock | S - Open market or private sale | -3,357 | $2.71 |
Jan 17/24 | Jan 16/24 | Mandelia Ashish | Direct Ownership | Common Stock | S - Open market or private sale | -5,025 | $2.71 |
Jan 17/24 | Jan 16/24 | Lowinger Timothy B | Direct Ownership | Common Stock | S - Open market or private sale | -10,409 | $2.71 |
Jan 17/24 | Jan 16/24 | Carvajal Alejandra | Direct Ownership | Common Stock | S - Open market or private sale | -4,381 | $2.71 |
Jan 17/24 | Jan 16/24 | DeSchuytner Brian | Direct Ownership | Common Stock | S - Open market or private sale | -9,327 | $2.71 |
Jan 17/24 | Jan 16/24 | Bala Mohan | Direct Ownership | Common Stock | S - Open market or private sale | -3,431 | $2.71 |
Jan 17/24 | Jan 15/24 | Protopapas Anna | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,708 | |
Jan 17/24 | Jan 15/24 | Protopapas Anna | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 21,250 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for MRSN within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 3/24 | Apr 1/24 | Alleva Lawrence M | Direct Ownership | Stock Option (right to buy) | A - Grant, award or other under Rule 16b-3(d) | 3,996 | |
Jan 17/24 | Jan 14/24 | Protopapas Anna | Direct Ownership | Restricted Stock Unit | M - Exercise or conversion exempt under rule 16b-3 | -16,750 | |
Jan 17/24 | Jan 13/24 | Protopapas Anna | Direct Ownership | Restricted Stock Unit | M - Exercise or conversion exempt under rule 16b-3 | -31,250 | |
Jan 17/24 | Jan 16/24 | Protopapas Anna | Direct Ownership | Common Stock | S - Open market or private sale | -29,399 | $2.71 |
Jan 17/24 | Jan 15/24 | Protopapas Anna | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,708 | |
Jan 17/24 | Jan 15/24 | Protopapas Anna | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 21,250 | |
Jan 17/24 | Jan 14/24 | Protopapas Anna | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 16,750 | |
Jan 17/24 | Jan 15/24 | Protopapas Anna | Direct Ownership | Restricted Stock Unit | M - Exercise or conversion exempt under rule 16b-3 | -17,708 | |
Jan 17/24 | Jan 15/24 | Protopapas Anna | Direct Ownership | Restricted Stock Unit | M - Exercise or conversion exempt under rule 16b-3 | -21,250 | |
Jan 17/24 | Jan 13/24 | Protopapas Anna | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 31,250 | |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Neurocrine Biosciences (OQ:NBIX) |
Regeneron Pharmaceuticals (OQ:REGN) |
Madrigal Pharmaceuticals (OQ:MDGL) |